Standardized Remission Criteria in Schizophrenia: Descriptive Validity and Comparability with Previously Used Outcome Measures

Jäger, Markus; Messer, Thomas; Laux, Gerd; Pfeiffer, Herbert; Lg, Schmidt; Gäebel, Wolfgang; Klosterkötter, Joachim; Heuser, Isabella; Maier, W.; Mr, Lemke; Rüther, Eckart; Buchkremer, G; Gastpar, Markus; Riedel, Michael; Bottlender, R.; Strauß, Anton; Møller, Henrik

doi:10.1055/s-2008-1078745

Cited by 20 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the fact that baseline data from an ongoing, prospective follow-up study was used, as suggested by the Remission of Schizophrenia Working Group severity was adopted in evaluating clinical remission, whilst duration was not taken into account. Moreover, to define a state of clinical remission [47], a CGI-SCH score equal or less than 3 was required. Given that the criteria published by Andreasen for clinical remission are based on eight selected items from PANSS, thus excluding all items which significantly contribute towards overall clinical picture and quality of life, such as depressive and other symptoms [48], we decided to apply other more restrictive criteria.…”

Section: Methodsmentioning

confidence: 99%

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study

Carpiniello

Pinna

Tusconi

et al. 2012

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

The aim of the paper was to evaluate rates of clinical remission and recovery according to gender in a cohort of chronic outpatients attending a university community mental health center who had been diagnosed with schizophrenia and schizoaffective disorder according to DSM-IV-TR. A sample of 100 consecutive outpatients (70 males and 30 females) underwent comprehensive psychiatric evaluation using the Structured Clinical Interview for Diagnosis of Axis I and II DSM-IV (SCID-I and SCID-II, Version R) and an assessment of psychopathology, social functioning, clinical severity, subjective wellbeing, and quality of life, respectively by means of PANSS (Positive and Negative Syndrome Scale), PSP (Personal and Social Performance), CGI-SCH (Clinical Global Impression—Schizophrenia scale), SWN-S (Subjective Well-being under Neuroleptics—scale), and WHOQOL (WHO Quality of Life). Rates of clinical remission and recovery according to different criteria were calculated by gender. Higher rates of clinical remission and recovery were generally observed in females than males, a result consistent with literature data. Overall findings from the paper support the hypothesis of a better outcome of the disorders in women, even in the very long term.

show abstract

Section: Methodsmentioning

confidence: 99%

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study

Carpiniello

Pinna

Tusconi

et al. 2012

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

show abstract

“…On the other hand, at stable state, both positive and negative symptoms have been shown to covary with elevated bilirubin [12] , a fi nding that might be confi ned to schizophrenia rather than ATPD patients who are supposed to fully recover after acute psychosis (although note that full recovery is diffi cult to operationalise, [7] ). More importantly, diff erent aetiology of acute psychoses and schizophrenia has been proposed and might account for diff ering bilirubin levels.…”

Section: Diagnosismentioning

confidence: 98%

Elevated Bilirubin in Acute and Transient Psychotic Disorder

2009

View full text Add to dashboard Cite

show abstract

“…Comorbid OCS in schizophrenia is associated with pronounced positive and negative symptoms [7], lower levels of social functioning, higher treatment costs, worse social and vocational rehabilitation. Consequently they have a less favourable prognosis [8-11], in particular if recent concepts of response, remission and recovery [12,13] are applied. These well-documented facts correct former concepts, where comorbid OCS in schizophrenia were assumed to have protective effects regarding psychotic desintegration [14-18].…”

Section: Obsessive-compulsive Symptoms In Schizophreniamentioning

confidence: 99%

Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review

Schirmbeck¹,

Zink

2012

110

104

View full text Add to dashboard Cite

Obsessive-compulsive disorder (OCD) is rarely associated with schizophrenia, whereas 20 to 30% of schizophrenic patients, suffer from comorbid obsessive-compulsive symptoms (OCS). So far no single pathogenetic theory convincingly explained this fact suggesting heterogeneous subgroups. Based on long-term case observations, one hypothesis assumes that second-onset OCS in the course of schizophrenia might be a side effect of second generation antipsychotics (SGA), most importantly clozapine (CLZ). This review summarizes the supporting epidemiological and pharmacological evidence: Estimations on prevalence of OCS increase in more recent cross-sectional studies and in later disease stages. Longitudinal observations report the de novo-onset of OCS under clozapine treatment. This association has not been reported with first generation antipsychotics (FGA) or SGAs with mainly dopaminergic mode of action. Finally, significant correlations of OCS-severity with duration of treatment, dose and serum levels suggest clozapine-induced OCS. However, supposed causal interactions need further verifications. It is also unclear, which neurobiological mechanisms might underlie the pathogenetic process. Detailed genotypic and phenotypic characterizations of schizophrenics with comorbid OCS regarding neurocognitive functioning and activation in sensitive tasks of functional magnetic imaging are needed. Multimodal large-scaled prospective studies are necessary to define patients at risk for second-onset OCS and to improve early detection and therapeutic interventions.

show abstract

Standardized Remission Criteria in Schizophrenia: Descriptive Validity and Comparability with Previously Used Outcome Measures

Abstract: The results indicate a high descriptive validity of the symptom-severity component of the proposed remission definition. However, the new criteria differ partially from previously used outcome measures. This aspect should be considered in the interpretation of clinical trials.

Cited by 20 publications

References 30 publications

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study

Elevated Bilirubin in Acute and Transient Psychotic Disorder

Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review

Contact Info

Product

Resources

About